03.08.2010 • News • Mergers & Acquisitions (M&A) • Genzyme • Sanofi

Sanofi Sends Offer Letter to Genzyme

Sanofi-Aventis has sent Genzyme a letter indicating its interest in buying the company and the two sides are discussing the offer, a source familiar with the situation said on Monday.

The source familiar with the situation also said that Genzyme was not likely to accept a deal under $80 per share. Sanofi had been expected to send a formal bid for Genzyme over the weekend, but no details on the price or the structure of a potential deal were immediately available.

Sanofi's board last week authorized the company to press ahead with a formal offer for Genzyme worth up to $70 per share, or $18.7 billion, sources told Reuters at the time.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.